¡Ø Ãß¼® ¿¬ÈÞ ÈÞ¹«¾È³» : 2024³â 9¿ù 16ÀÏ(¿ù) ~ 2024³â 9¿ù 18ÀÏ(¼ö)

½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1535853

µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå : µ¿¹° À¯Çü, Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2024-2032³â)

Veterinary Regenerative Medicine Market - By Animal Type, Product Type, Application, End-user - Global Forecast 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀå ±Ô¸ð´Â µ¿¹° ¸¸¼ºÁúȯ ¹× Á¤Çü¿Ü°úÀû ¹®Á¦ÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ 2024-2032³â¿¡ CAGR 9.9%¸¦ ±â·ÏÇÒ Àü¸ÁÀÔ´Ï´Ù. ¹Ý·Áµ¿¹° »çÀ°·üÀÌ Áõ°¡Çϸ鼭 ÷´Ü ¼öÀÇÇÐ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÏ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ¹Ý·Áµ¿¹° ¿ëÇ° Çùȸ¿¡ µû¸£¸é 2022³â ¹Ì±¹ °¡±¸ÀÇ 68%°¡ ¹Ý·Áµ¿¹°À» Å°¿ï °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áٱ⼼Æ÷ Ä¡·á¿Í Á¶Á÷°øÇÐÀ» Æ÷ÇÔÇÑ Àç»ýÀÇÇÐÀº µ¿¹°ÀÇ °ñ°üÀý¿°, ÈûÁÙ ¼Õ»ó, ½ÉÀå Áúȯ µîÀÇ Áõ»óÀ» Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ¹Ý·Áµ¿¹°ÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃÅ°°í ¼ö¸íÀ» ¿¬ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À±â¼úÀÇ ¹ßÀü°ú ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡µµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¬±¸±â°ü, µ¿¹°º´¿ø, Á¦¾àȸ»çÀÇ Çù·ÂÀ¸·Î È¿°úÀûÀÎ Àç»ý Ä¡·á¹ýÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Journal of Veterinary ScienceÀÇ 2023³â ¿¬±¸¿¡ µû¸£¸é Áٱ⼼Æ÷ Ä¡·á¸¦ ¹ÞÀº ¹Ý·Á°ßÀÇ °ñ°üÀý¿° Áõ»óÀÌ 20% °³¼±µÈ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú Àç»ýÀÇ·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ¼öÀÇÇÐ Àü¹®°¡µéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Ä¡·á¹ý µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í Çõ½ÅÀûÀÎ Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀüÀº Ä¡·áÀÇ È¿°ú¿Í Á¢±Ù¼ºÀ» Çâ»ó½ÃÅ°¸ç ¾÷°è Àü¸ÁÀ» Çü¼ºÇÏ°í ÀÖ½À´Ï´Ù.

»ý¹°ÇÐÀû Ä¡·á ºÎ¹®Àº ÁÖ·Î ÀÌ·¯ÇÑ Ä¡·áÀÇ È¿°ú¿Í Çõ½ÅÀûÀΠƯ¼ºÀ¸·Î ÀÎÇØ 2032³â±îÁö °­·ÂÇÑ ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »ý¹°ÇÐÀû Ä¡·á´Â Àç»ý ´É·Â°ú ±Ù°ñ°Ý°è ¼Õ»ó, »óó Ä¡À¯, ¸¸¼º ¿°Áõ¼º Áúȯ°ú °°Àº ´Ù¾çÇÑ µ¿¹° »óŸ¦ Ä¡·áÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ¸·Î ÀÎÇØ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ½ÅüÀÇ ÀÚ¿¬ Ä¡À¯ °úÁ¤À» È°¿ëÇÏ¿© ±âÁ¸ Ä¡·á¹ý¿¡ ´ëÇÑ ÃÖ¼Ò Ä§½ÀÀûÀÌ°í ¸Å¿ì È¿°úÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. »ý¹°ÇÐÀû Ä¡·áÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Áö¿øÇÏ´Â ÀÓ»óÀû Áõ°ÅÀÇ ÃàÀû°ú ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â µ¿¹°º´¿ø¿¡¼­ »ý¹°ÇÐÀû Ä¡·áÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù.

¹Ý·Áµ¿¹°°ú °¡ÃàÀÇ ºÎ»ó°ú ¼ö¼úÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿Ü»ó ¹× »óó Ä¡·á ¿ëµµ´Â 2032³â±îÁö ÁÖ¸ñÇÒ ¸¸ÇÑ ¾÷°è Á¡À¯À²À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áٱ⼼Æ÷ Ä¡·á ¹× ´ÙÇ÷¼ÒÆÇ Ç÷Àå(PRP)°ú °°Àº Àç»ý Ä¡·á´Â Ä¡À¯¸¦ ÃËÁøÇÏ°í ¿°ÁõÀ» °¨¼Ò½ÃÅ°¸ç ÈäÅ͸¦ ÃÖ¼ÒÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü Ä¡·á¹ýÀº ±âÁ¸ Ä¡·á¹ýÀ» ´ëüÇÒ ¼ö ÀÖ´Â º¸´Ù È¿°úÀûÀÌ°í ´ú ħ½ÀÀûÀÎ Ä¡·á¹ýÀ» Á¦°øÇÏ¿© µ¿¹°ÀÇ Ä¡·á °á°ú¸¦ °³¼±ÇÏ°í ȸº¹ ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿Ü»ó ¹× »óó Ä¡·á¿¡ ÀÖÀ¸¸ç, Àç»ýÀÇ·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ¼öÀÇ»ç¿Í ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í, Ä¡·á ¹æ¹ý°ú Á¦Ç°ÀÇ °¡¿ë¼ºÀÌ Áö¼ÓÀûÀ¸·Î ¹ßÀüÇÔ¿¡ µû¶ó ÀÌ ºÐ¾ß°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µ¿¹°¿ë Àç»ýÀÇ·á ½ÃÀåÀº 2032³â±îÁö Å« ÆøÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ƯÈ÷ µµ½Ã Áö¿ª¿¡¼­ÀÇ ¹Ý·Áµ¿¹° »çÀ° Áõ°¡´Â ÷´Ü ¼öÀÇÇÐ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° º¸È£ÀÚ¿Í ¼öÀÇ»çµé »çÀÌ¿¡¼­ Áٱ⼼Æ÷ Ä¡·á¿Í Á¶Á÷°øÇÐ µî Àç»ýÄ¡·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¿¹° ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¿Í °¡Ã³ºÐ ¼Òµæ Áõ°¡·Î ÀÎÇØ ÀÌ·¯ÇÑ Çõ½ÅÀû Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÁýÁßÀûÀÎ ³ë·ÂÀº Çаè¿Í »ý¸í°øÇÐ ±â¾÷ °£ÀÇ Çù·Â¿¡ ÈûÀÔ¾î ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ µ¿¹°À» À§ÇÑ »õ·Î¿î Àç»ýÀÇ·áÀÇ µµÀÔÀ» ´õ¿í °¡¼ÓÈ­ÇÏ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¾÷°è ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • ¾Ö¿Ïµ¿¹° Àα¸ : ±¹°¡º°
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : µ¿¹° À¯Çüº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ¾Ö¿Ïµ¿¹°
  • Ãà»ê µ¿¹°

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Á¦Ç° À¯Çüº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • Áٱ⼼Æ÷ Ä¡·á
    • ÀÚ°¡
    • µ¿Á¾
  • »ý¹°ÇÐÀû ¿ä¹ý
    • Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP)
    • ¼ºÀåÀÎÀÚ
  • Á¶Á÷°øÇÐ

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¿ëµµº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • Á¤Çü¿Ü°ú
  • ¿Ü»ó¡¤Ã¢»ó Ä¡·á
  • ±âŸ ¿ëµµ

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • µ¿¹°º´¿ø
  • µ¿¹° Ŭ¸®´Ð
  • Çмú¡¤¿¬±¸±â°ü

Á¦9Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • Animal Cell Therapies, Inc.
  • Ardent
  • Bioceltix
  • Boehringer Ingelheim International GmbH
  • CTSL(Cell Therapy Sciences)
  • Dechra
  • Enso Discoveries
  • Magellan Stem Cells
  • Medrego
  • Regeneus Ltd(Cambium Bio Ltd.)
  • StemcellX
  • VetStem, Inc.
  • Zoetis Inc.
KSA 24.08.26

The veterinary regenerative medicine market is poised to record 9.9% CAGR during 2024-2032, due to the increasing prevalence of chronic ailments and orthopedic issues in animals. With pet ownership rising, the demand for advanced veterinary solutions has surged. According to the American Pet Products Association, 68% of U.S. households owned a pet in 2022. Regenerative medicine, including stem cell therapy and tissue engineering, offers treatments for conditions like osteoarthritis, tendon injuries, and cardiac diseases in animals. These therapies improve pets' quality of life and extend their lifespans.

Advancements in biotechnology and increased R&D investments are also driving the market growth. Collaborations between research institutions, veterinary clinics, and pharmaceutical companies are developing effective regenerative therapies. For instance, a 2023 study by the Journal of Veterinary Science highlighted a 20% improvement in osteoarthritis symptoms in dogs treated with stem cell therapy. Regulatory approvals for new treatments and growing awareness among veterinary professionals about regenerative medicine's benefits are favoring adoption. The trend towards personalized medicine and innovative delivery systems enhances treatment efficacy and accessibility, shaping the industry outlook.

The overall veterinary regenerative medicine industry is classified based on animal type, product type, application, end-user, and region.

The biological therapy segment is slated to record robust growth through 2032, primarily due to the efficacy and innovative nature of these treatments. Biological therapies are utilized for their regenerative capabilities and potential to treat a variety of animal conditions such as musculoskeletal injuries, wound healing, and chronic inflammatory diseases. These therapies leverage the body's natural healing processes, offering a minimally invasive and highly effective alternative to traditional treatments. The growing body of clinical evidence supporting the safety and effectiveness of biological therapies, along with rising investment in R&D, is driving their adoption in veterinary practices.

The trauma/wound care application segment will register notable industry share by 2032, due to the increasing prevalence of injuries and surgical procedures among pets and livestock. Regenerative therapies, such as stem cell treatments and platelet-rich plasma (PRP), accelerate healing, reduce inflammation, and minimize scarring. These advanced therapies provide a more effective and less invasive alternative to conventional treatments, leading to improved outcomes and faster recovery times for animals. The growing awareness among veterinarians and pet owners about the benefits of regenerative medicine for trauma and wound care, coupled with ongoing advancements in treatment methodologies and product availability, is driving the expansion of this segment.

Asia Pacific veterinary regenerative medicine market is poised for substantial growth through 2032. Increasing pet ownership, especially in urban areas, is contributing to a rising demand for advanced veterinary care solutions. There is growing awareness among pet owners and veterinarians about the benefits of regenerative therapies, such as stem cell treatments and tissue engineering. Additionally, significant investments in veterinary healthcare infrastructure and rising disposable incomes are enabling greater access to these innovative treatments. The region's strong focus on R&D, supported by collaborations between academic institutions and biotechnology firms, is further accelerating the introduction of novel regenerative medicine for animals across Asia Pacific.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of chronic and degenerative conditions
      • 3.2.1.2 Growing advancement in regenerative medicine
      • 3.2.1.3 Increasing R&D investment and activities
      • 3.2.1.4 Growing pet ownership and spendings
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects of the treatment
      • 3.2.2.2 Regulatory challenges
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Pet population, by country
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Companion animals
  • 5.3 Livestock animals

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Stem cell therapy
    • 6.2.1 Autologous
    • 6.2.2 Allogeneic
  • 6.3 Biological therapy
    • 6.3.1 Platelet-rich plasma (PRP)
    • 6.3.2 Growth factors
  • 6.4 Tissue engineering

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Orthopedics
  • 7.3 Trauma/ wound care
  • 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Veterinary hospitals
  • 8.3 Veterinary clinics
  • 8.4 Academics and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Animal Cell Therapies, Inc.
  • 10.2 Ardent
  • 10.3 Bioceltix
  • 10.4 Boehringer Ingelheim International GmbH
  • 10.5 CTSL (Cell Therapy Sciences)
  • 10.6 Dechra
  • 10.7 Enso Discoveries
  • 10.8 Magellan Stem Cells
  • 10.9 Medrego
  • 10.10 Regeneus Ltd (Cambium Bio Ltd.)
  • 10.11 StemcellX
  • 10.12 VetStem, Inc.
  • 10.13 Zoetis Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦